Literature DB >> 29147850

The tear cytokine profile in patients with active Graves' orbitopathy.

Morgan Yang1,2, Yvonne Chung3,4, Stephanie Lang3, Nobuyo Yawata4,5, Lay Leng Seah3,4, Audrey Looi3,4.   

Abstract

PURPOSE: The primary aim of this study is to isolate cytokines specific for active Graves' orbitopathy (GO) in the tears of affected patients. The secondary aim is to identify other cytokines of interest and to look at the profile of their levels over time.
METHODS: This is a prospective pilot study conducted at the Singapore National Eye Centre. A total of 10 patients with active GO and 10 patients from each of 3 control groups were recruited. The 3 control groups were the following: age-matched normal female patients, patients with GO who were clinically inactive and patients with bilateral viral conjunctivitis. Tears from patients from the control groups were collected on a single visit. For patients with active GO, tears were collected on presentation, at 6 months, 12 months and 18 months.
RESULTS: Of all the cytokines examined, only IL-7 yielded a difference when the concentration in patients with active GO was compared with concentrations in all the control groups. This difference was most significant at the 18-month follow-up visit.
CONCLUSIONS: Low concentrations of IL-7 in tears exhibit specificity for active GO in patients nearly 2 years from the clinical onset of activity. Although using IL-7 in tears as a biomarker for disease activity may be limited due to its late manifestation, targeting immune restitution using IL-7 may have disease modifying effects.

Entities:  

Keywords:  Active; Cytokines; Eye; Graves’; Specificity; Tears

Mesh:

Substances:

Year:  2017        PMID: 29147850     DOI: 10.1007/s12020-017-1467-2

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  30 in total

1.  CT dimensions of the lacrimal gland in Graves orbitopathy.

Authors:  Matheson A Harris; Tony Realini; Jeffrey P Hogg; Jennifer A Sivak-Callcott
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2012 Jan-Feb       Impact factor: 1.746

2.  Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy.

Authors:  M P Mourits; M F Prummel; W M Wiersinga; L Koornneef
Journal:  Clin Endocrinol (Oxf)       Date:  1997-07       Impact factor: 3.478

3.  Interleukin-7: a key mediator in T cell-driven autoimmunity, inflammation, and tissue destruction.

Authors:  Angela Bikker; C Erik Hack; Floris P J G Lafeber; Joel A G van Roon
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 4.  Interleukin-6: structure-function relationships.

Authors:  R J Simpson; A Hammacher; D K Smith; J M Matthews; L D Ward
Journal:  Protein Sci       Date:  1997-05       Impact factor: 6.725

Review 5.  Endocrine ophthalmopathy: current ideas concerning etiology, pathogenesis, and treatment.

Authors:  D H Jacobson; C A Gorman
Journal:  Endocr Rev       Date:  1984       Impact factor: 19.871

6.  Soluble interleukin-1 receptor antagonist concentration in patients with Graves' ophthalmopathy is neither related to cigarette smoking nor predictive of subsequent response to glucocorticoids.

Authors:  L Bartalena; L Manetti; M L Tanda; E Dell'Unto; B Mazzi; R Rocchi; G Barbesino; A Pinchera; C Marcocci
Journal:  Clin Endocrinol (Oxf)       Date:  2000-05       Impact factor: 3.478

7.  Proinflammatory cytokine profiling of tears from dry eye patients by means of antibody microarrays.

Authors:  Nils Boehm; Aline I Riechardt; Michaela Wiegand; Norbert Pfeiffer; Franz H Grus
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-09-29       Impact factor: 4.799

8.  Cell-mediated or humoral immunity in Graves' ophthalmopathy? Profiles of T-cell cytokines amplified by polymerase chain reaction from orbital tissue.

Authors:  S M McLachlan; M F Prummel; B Rapoport
Journal:  J Clin Endocrinol Metab       Date:  1994-05       Impact factor: 5.958

9.  Analysis of tear cytokines and clinical correlations in Sjögren syndrome dry eye patients and non-Sjögren syndrome dry eye patients.

Authors:  Sang Yeop Lee; Soo Jung Han; Sang Min Nam; Sang Chul Yoon; Ji Min Ahn; Tae-Im Kim; Eung Kweon Kim; Kyoung Yul Seo
Journal:  Am J Ophthalmol       Date:  2013-06-07       Impact factor: 5.258

Review 10.  Diagnostic criteria for Graves' ophthalmopathy.

Authors:  G B Bartley; C A Gorman
Journal:  Am J Ophthalmol       Date:  1995-06       Impact factor: 5.258

View more
  4 in total

1.  Proteomics of Tear in Inactive Thyroid-Associated Ophthalmopathy.

Authors:  L Jiang; R Wei; J Diao; H Ding; W Wang; R Ao
Journal:  Acta Endocrinol (Buchar)       Date:  2021 Jul-Sep       Impact factor: 0.877

2.  A systematic review of multimodal clinical biomarkers in the management of thyroid eye disease.

Authors:  Stephanie Hiu Ling Poon; Janice Jing-Chee Cheung; Kendrick Co Shih; Yau Kei Chan
Journal:  Rev Endocr Metab Disord       Date:  2022-01-23       Impact factor: 6.514

3.  Tear proteomics of orbital decompression for disfiguring exophthalmos in inactive thyroid-associated ophthalmopathy.

Authors:  Lihong Jiang; Ao Rong; Ruili Wei; Jiale Diao; Hui Ding; Wei Wang
Journal:  Exp Ther Med       Date:  2020-10-23       Impact factor: 2.447

4.  The value of SPECT/CT imaging of lacrimal glands as a means of assessing the activity of Graves' orbitopathy.

Authors:  Ru-Xuan Zhao; Ting-Ting Shi; Sha Luo; Yun-Fu Liu; Zhong Xin; Jin-Kui Yang
Journal:  Endocr Connect       Date:  2022-02-09       Impact factor: 3.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.